Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415260 | 1.00 | MCHR1 (0.54) | MCHR1NR1H4PARP15PARP10PARP2 | |
| SCHEMBL354944 | 0.93 | MCHR1 (0.47) | MCHR1NR1H4PARP15PARP10PARP2 | |
| SCHEMBL354945 | 0.93 | MCHR1 (0.47) | MCHR1NR1H4PARP15PARP10PARP2 | |
| SCHEMBL420147 | 0.86 | MCHR1 (0.72) | MCHR1 | |
| SCHEMBL420148 | 0.86 | MCHR1 (0.72) | MCHR1 | |
| SCHEMBL420200 | 0.85 | MCHR1 (0.69) | MCHR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL420199 | 0.85 | MCHR1 (0.69) | MCHR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL420113 | 0.84 | MCHR1 (0.51) | MCHR1NR1H4PARP15PARP10PARP2 | |
| SCHEMBL420114 | 0.84 | MCHR1 (0.51) | MCHR1NR1H4PARP15PARP10PARP2 | |
| SCHEMBL356088 | 0.79 | TAOK1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552199-B2 | Substituted indanes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2396298-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092154-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | MCHR1, MCHR2, IDO1 | MCHR1 1/4885NR1H4 159/4885PARP15 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.